A Phase 1 interventional study of Gepotidacin RC Tablet and Gepotidacin HSWG Tablet in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 1, and was the 5th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2016.
This study's enrollment of 48 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2016, is one of 28 in phase 1, and was the 26th registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is divided in 2 parts. Part 1a is being conducted to evaluate the safety, tolerability, and relative bioavailability of the 2 free base tablet formulations (roller compacted [RC] and high shear wet granulation [HSWG]) compared to the reference capsule formulation under fasted conditions. This is a 3-period; cross-over study that will guide which gepotidacin formulation will be used for future studies. Following review of pharmacokinetic (PK) and safety data in Part 1a, a decision will be made whether to proceed with Parts 1b and 2.
Part 1b is a 2-period, cross-over study and will assess the effect of food on the PK of the selected gepotidacin tablet formulation from Part 1a. In Part 2, the PK of the selected gepotidacin tablet formulation from Part 1a in Japanese (2a) and Chinese (2b) subjects will be evaluated under fasted conditions.
The duration of the study (from Screening to the Follow-up visit) will be approximately 44 days (Part 1a), 41 days (Part 1b) and 38 days (Part 2a and 2b each), respectively. The approximate number of subjects enrolled in Part 1a will be 27 (9 subjects in each of the 3 treatment sequences), 16 in Part 1b (8 subjects in each of the 2 treatment sequences) and 12 Japanese and 12 Chinese subjects in Part 2a and 2b, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet · Drug: Gepotidacin Capsule
Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet · Drug: Gepotidacin Capsule
Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet · Drug: Gepotidacin Capsule
Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet
Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet
Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet
Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
Drug: Gepotidacin RC Tablet · Drug: Gepotidacin HSWG Tablet
The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of Plasma Gepotidacin for Part 1a
Blood samples for pharmacokinetic (PK) analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 milliliters (mL) of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. The PK Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. Statistics has been presented on geometric least square (LS) means.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Area Under the Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC [0-t]) of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Statistics has been presented on geometric LS means.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Relative Bioavailability of Drug (Frel) of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. NA indicates data was not available as this was the reference capsule the Frel of each tablet type was being compared to.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Maximum Observed Concentration (Cmax) Determined Directly From the Concentration Time Data of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Statistics has been presented on geometric LS means.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Time to First Occurrence of Cmax (Tmax) of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Terminal Phase Half-life (t1/2) of Plasma Gepotidacin for Part 1a
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Total Unchanged Drug (Total Amount of Drug Excreted in Urine [Ae Total]) for Part 1a
PK urine samples were collected at 0 (predose), 0 to 2, 2 ot 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Plasma Gepotidacin for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Renal Clearance of Drug in Urine (CLr) for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Amount of Drug Excreted in Urine in a Time Intervals for Pre-dose, 0 to 2 Hours, 2 to 4 Hours, 4 to 6 Hours, 6 to 8 Hours, 8 to 12 Hours, 12 to 24 Hours, 24 to 36 Hours, and 36 to 48 Hours (Ae [t1-t2]) for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants available at the specific time points were analyzed (represented by n = X in the category titles).
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 12 Hours (AUC [0-12]) for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 24 Hours (AUC [0-24]) After Dosing for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 48 Hours (AUC [0-48]) After Dosing for Part 1a
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants with data available at the indicated time point were analyzed.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
AUC (0-infinity) of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
AUC (0-t) of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Cmax of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tmax of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tlag of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
t1/2 of Plasma Gepotidacin for Part 1b
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
AUC (0-infinity) of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
AUC (0-t) of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Cmax of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tlag of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tmax of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
t1/2 of Plasma Gepotidacin for Part 2
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Total Unchanged Drug (Ae Total) for Part 2
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Ae (t1-t2) for Part 2
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
AUC (0-12) for Part 2
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
AUC (0-24) for Part 2
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
AUC (0-48) for Part 2
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
fe% for Part 2
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
CLr for Part 2
PK urine samples were collected at pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
AUC (0-infinity) of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
AUC (0-t) of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Cmax of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tmax of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Tlag of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
t1/2 of Plasma Gepotidacin for Part 3
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in each treatment period
Total Unchanged Drug (Ae Total) for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours
Urine Ae (t1-t2) for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants available at the specific time points were analyzed (represented by n = X in the category titles).
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Urine AUC (0-12) for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Urine AUC (0-24) for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Urine AUC (0-48) for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
fe% for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
CLr for Part 3
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
Time frame: Pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, and 36 to 48 hours.
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) for Part 1a
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Participants with non-serious AEs and SAEs has been reported. Safety Population comprised of all participants who received at least 1 dose of study medication and had at least 1 post dose safety assessment.
Time frame: Up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 1a
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Alanine Aminotransferase (ALT), Serum Alkaline Phosphatase (AP), Serum Aspartate Aminotransferase (AST) and Serum Creatinine Kinase (CK) for Part 1a
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 1a
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin for Part 1a
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin, serum creatinine and serum direct bilirubin Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 1a
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameters Blood Erythrocyte (Ery.) Mean Corpuscular Hemoglobin Concentration (MCHC) and Blood Hemoglobin for Part 1a
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Hemoglobin (MCH) for Part 1a
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Volume (MCV) for Part 1a
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. for Part 1a
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Hematocrit for Part 1a
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Vital Sign Parameters Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) for Part 1a
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Vital Sign Parameter Heart Rate for Part 1a
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in Electrocardiogram (ECG) Parameter Heart Rate for Part 1a
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and Corrected QT Interval Using Fridericia's Formula (QTcF) for Part 1a
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 1a. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
Time frame: Baseline and up to 14 days
Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 1a
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 1a. Only categories with significant values have been presented.
Time frame: Up to 14 days
Number of Participants With AEs and SAEs for Part 1b
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 1b
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK for Part 1b
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 1b
Blood samples were collected for the assessment of chemistry parameters namely serum albuim and serum protein for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin in Part 1b
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 1b
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameters Blood Ery. MCHC and Blood Hemoglobin for Part 1b
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 1b
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. MCV for Part 1b
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. for Part 1b
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Hematocrit for Part 1b
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Vital Sign Parameters SBP and DBP for Part 1b
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in Vital Sign Parameter Heart Rate for Part 1b
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in ECG Parameter Heart Rate for Part 1b
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 1b
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 1b. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Baseline and up to 11 days
Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 1b
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
Time frame: Up to 11 days
Number of Participants With Non-serious AEs and SAEs for Part 2
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
Time frame: Up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen in Part 2
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK in Part 2
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 2
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin, Serum Creatinine and Serum Direct Bilirubin for Part 2
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin, serum creatinine and serum direct bilirubin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Clinical Chemistry Parameter Serum Estradiol for Part 2
Blood samples were collected for the assessment of chemistry parameter namely serum estradiol for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the indicated time point were analyzed. NA indicates standard deviation was not calculated as a single participant was analyzed.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 2
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameters Ery. MCHC and Blood Hemoglobin for Part 2
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 2
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. MCV for Part 2
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Ery. for Part 2
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Hematology Parameter Blood Hematocrit for Part 2
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Vital Sign Parameters SBP and DBP for Part 2
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in Vital Sign Parameter Heart Rate for Part 2
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in ECG Parameter Heart Rate for Part 2
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 2
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 2. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
Time frame: Baseline and up to 11 days
Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 2
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 4+ 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 2. Only categories with significant values have been presented.
Time frame: Baseline and up to 11 days
Number of Participants With Non-serious AEs and SAEs for Part 3
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
Time frame: Up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Glucose, Serum Calcium, Serum Carbon Dioxide, Serum Chloride, Serum Potassium, Serum Sodium and Serum Urea Nitrogen for Part 3
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum ALT, Serum AP, Serum AST and Serum CK for Part 3
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Albumin and Serum Protein for Part 3
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Clinical Chemistry Parameters Serum Bilirubin and Serum Creatinine for Part 3
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin and serum creatinine for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameters Blood Basophils, Blood Eosinophils, Blood Leukocytes, Blood Lymphocytes, Blood Monocytes, Blood Neutrophils and Blood Platelets for Part 3
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameters Blood Ery. MCHC and Blood Hemoglobin for Part 3
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. MCH for Part 3
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. Mean Corpuscular Volume (MCV) for Part 3
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Ery. for Part 3
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Hematology Parameter Blood Hematocrit for Part 3
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Vital Sign Parameters SBP and DBP for Part 3
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in Vital Sign Parameter Heart Rate for Part 3
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in ECG Parameter Heart Rate for Part 3
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Change From Baseline in ECG Parameters PR Interval, QRS Duration, QT Interval, QTcB and QTcF for Part 3
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 3. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
Time frame: Baseline and up to 14 days
Number of Participants With Abnormal Values on Urinalysis by Dipstick Analysis Part 3
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 3. Only categories with significant values have been presented.
Time frame: Up to 14 days
This study was conducted across 2 centers in the United States from 04-August-2016 to 18-October-2017. Since the relative bio-availability of the roller compacted(RC) tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 0 | 0 | 0 |
| Completed | 9 | 9 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 0 | 0 | 0 |
| Completed | 9 | 9 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 0 | 0 | 0 |
| Completed | 9 | 9 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 0 | 0 | 0 |
| Completed | 9 | 9 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 0 | 0 | 0 |
| Completed | 9 | 9 | 8 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 | 0 | 0 |
| Completed | 0 | 0 | 0 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 2 |
| Completed | 0 | 0 | 0 | 0 | 10 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 2 |
| Completed | 0 | 0 | 0 | 0 | 10 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 2 |
| Completed | 0 | 0 | 0 | 0 | 10 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 2 |
| Completed | 0 | 0 | 0 | 0 | 9 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Gepotidacin-R Then Gepotidacin RC Then Gepotidacin HSWG | Gepotidacin HSWG Then Gepotidacin- R Then Gepotidacin RC | Gepotidacin-RC Then Gepotidacin HSWG Then Gepotidacin-R | Gepotidacin 1500 mg RC Then Gepotidacin 3000 mg RC | Gepotidacin 1500 Then Gepotidacin 2250 Then Gepotidacin 3000 | Placebo Then Placebo Then Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 9 | 2 |
| Completed | 0 | 0 | 0 | 0 | 9 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples for pharmacokinetic (PK) analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 milliliters (mL) of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. The PK Parameter Population consisted of all participants in the PK Population, for whom valid and evaluable PK parameters were derived. Statistics has been presented on geometric least square (LS) means.
| hours*nanograms/milliliter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) of Plasma Gepotidacin for Part 1a | 16733 ± 25.7 | 17495 ± 23.0 | 18646 ± 24.0 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Statistics has been presented on geometric LS means.
| hours*nanograms/milliliters | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Time of the Last Quantifiable Concentration (AUC [0-t]) of Plasma Gepotidacin for Part 1a | 16409 ± 26.2 | 17125 ± 23.4 | 18317 ± 24.1 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. NA indicates data was not available as this was the reference capsule the Frel of each tablet type was being compared to.
| Ratio of AUC (0-infinity) | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Relative Bioavailability of Drug (Frel) of Plasma Gepotidacin for Part 1a | NA ± NA | 1.05 ± 22.3 | 1.11 ± 16.5 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Statistics has been presented on geometric LS means.
| nanograms/milliliter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) Determined Directly From the Concentration Time Data of Plasma Gepotidacin for Part 1a | 4648 ± 43.8 | 4487 ± 43.6 | 5349 ± 46.8 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Time to First Occurrence of Cmax (Tmax) of Plasma Gepotidacin for Part 1a | 1.50 (1.00 to 4.00) | 1.50 (0.50 to 4.00) | 1.00 (0.50 to 3.00) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of Plasma Gepotidacin for Part 1a | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.50) | 0.00 (0.00 to 0.50) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1a. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Terminal Phase Half-life (t1/2) of Plasma Gepotidacin for Part 1a | 10.29 ± 13.7 | 10.24 ± 15.2 | 10.24 ± 12.1 |
PK urine samples were collected at 0 (predose), 0 to 2, 2 ot 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
| milligrams | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Total Unchanged Drug (Total Amount of Drug Excreted in Urine [Ae Total]) for Part 1a | 274.925 ± 28.6 | 286.751 ± 22.2 | 284.510 ± 30.0 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| Percentage dose of drug excreted | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Plasma Gepotidacin for Part 1a | 18.329 ± 28.6 | 19.116 ± 22.2 | 18.968 ± 30.0 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| liters/hour | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Renal Clearance of Drug in Urine (CLr) for Part 1a | 16.761 ± 21.7 | 16.740 ± 19.6 | 15.532 ± 22.3 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants available at the specific time points were analyzed (represented by n = X in the category titles).
| milligrams | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Ae (0-2), n=26,25,26 | 65.817 ± 95.1 | 60.915 ± 102.9 | 85.584 ± 67.7 |
| Ae (2-4),n=26,24,25 | 72.734 ± 67.3 | 77.650 ± 33.6 | 67.419 ± 72.0 |
| Ae (4-6),n=25,25,26 | 36.019 ± 44.2 | 45.313 ± 61.1 | 39.361 ± 39.1 |
| Ae (6-8),n=25,26,26 | 22.817 ± 37.4 | 26.061 ± 24.9 | 22.755 ± 28.7 |
| Ae (8-12),n=26,26,26 | 21.515 ± 57.3 | 25.609 ± 27.7 | 16.590 ± 75.5 |
| Ae (12-24),n=26,26,26 | 19.224 ± 60.4 | 22.536 ± 26.9 | 19.432 ± 32.9 |
| Ae (24-36),n=26,26,26 | 8.145 ± 35.0 | 9.787 ± 27.8 | 8.185 ± 44.4 |
| Ae (36-48),n=26,26,26 | 4.633 ± 31.4 | 4.517 ± 57.7 | 4.319 ± 41.0 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
| micrograms*hours/milliliter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 12 Hours (AUC [0-12]) for Part 1a | 1904 ± 82.7 | 1948 ± 61.2 | 2156 ± 74.8 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
| micrograms*hours/milliliter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 24 Hours (AUC [0-24]) After Dosing for Part 1a | 2373 ± 74.9 | 2464 ± 56.3 | 2599 ± 69.0 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants with data available at the indicated time point were analyzed.
| micrograms*hours/milliliter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Area Under the Urine Concentration-time Curve Over Time 0 (Pre-dose) to 48 Hours (AUC [0-48]) After Dosing for Part 1a | 2597 ± 69.5 | 2725 ± 54.4 | 2768 ± 64.0 |
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin was planned to be collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 1b. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours*nanograms/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| AUC (0-infinity) of Plasma Gepotidacin for Part 2 | 23137 ± 34.1 | 46537 ± 20.9 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours*nanograms/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| AUC (0-t) of Plasma Gepotidacin for Part 2 | 22777 ± 34.4 | 46120 ± 21.1 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| nanograms/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Cmax of Plasma Gepotidacin for Part 2 | 9177 ± 94.8 | 15335 ± 28.6 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Tlag of Plasma Gepotidacin for Part 2 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Tmax of Plasma Gepotidacin for Part 2 | 1.00 (0.50 to 2.00) | 0.56 (0.50 to 2.50) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 2. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| t1/2 of Plasma Gepotidacin for Part 2 | 10.73 ± 10.9 | 8.81 ± 8.4 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| milligrams | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Total Unchanged Drug (Ae Total) for Part 2 | 203.853 ± 38.8 | 546.263 ± 51.8 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| milligrams | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Ae (0-2) | 50.893 ± 289.7 | 115.793 ± 73.0 |
| Ae (2-4) | 47.995 ± 42.7 | 131.013 ± 92.1 |
| Ae (4-6) | 21.381 ± 47.5 | 97.651 ± 139.4 |
| Ae (6-8) | 11.759 ± 88.2 | 40.670 ± 36.2 |
| Ae (8-12) | 12.519 ± 104.6 | 29.474 ± 96.0 |
| Ae (12-24) | 9.810 ± 226.4 | 30.849 ± 83.9 |
| Ae (24-36) | 3.710 ± 111.0 | 9.754 ± 51.0 |
| Ae (36-48) | 2.743 ± 114.7 | 3.652 ± 136.1 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| AUC (0-12) for Part 2 | 1298 ± 110.8 | 4758 ± 64.6 |
PK urine samples were collected at 0 (pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| AUC (0-24) for Part 2 | 1714 ± 88.8 | 5594 ± 61.9 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| AUC (0-48) for Part 2 | 1875 ± 83.6 | 5845 ± 61.1 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| Percentage dose of drug excreted | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| fe% for Part 2 | 13.591 ± 38.8 | 18.207 ± 51.8 |
PK urine samples were collected at pre-dose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| liters/hour | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| CLr for Part 2 | 8.950 ± 41.5 | 11.834 ± 32.0 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours*nanograms/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| AUC (0-infinity) of Plasma Gepotidacin for Part 3 | 22921 ± 19.9 | 37235 ± 17.2 | 50178 ± 21.9 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours*nanograms/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| AUC (0-t) of Plasma Gepotidacin for Part 3 | 22709 ± 20.0 | 36938 ± 17.2 | 49789 ± 21.7 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| nanograms/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Cmax of Plasma Gepotidacin for Part 3 | 6502 ± 27.7 | 9812 ± 21.1 | 12889 ± 21.1 |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Tmax of Plasma Gepotidacin for Part 3 | 2.25 (1.00 to 4.00) | 2.05 (1.50 to 4.00) | 2.00 (1.00 to 3.00) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Tlag of Plasma Gepotidacin for Part 3 | 0.50 (0.00 to 0.50) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Blood samples for PK analysis of gepotidacin were collected at Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours (Day 1), 24, 36 hours (Day 2) and 48 hours (Day 3) in Part 3. For each sample, 3 mL of blood was drawn via an indwelling catheter and/or direct venipuncture into tubes containing ethylenediaminetetraacetate anticoagulant. PK parameters were determined from the plasma concentration-time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| hours | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| t1/2 of Plasma Gepotidacin for Part 3 | 9.23 ± 9.7 | 8.19 ± 7.2 | 7.93 ± 10.6 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
| milligrams | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Total Unchanged Drug (Ae Total) for Part 3 | 390.099 ± 34.3 | 613.635 ± 32.2 | 895.556 ± 27.8 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher. Only those participants available at the specific time points were analyzed (represented by n = X in the category titles).
| milligrams | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Ae (0-2), n=10,10,9 | 27.763 ± 536.8 | 54.827 ± 264.1 | 142.546 ± 96.7 |
| Ae (2-4), n=10,10,9 | 132.423 ± 67.6 | 247.448 ± 45.5 | 333.805 ± 43.0 |
| Ae (4-6),n=9,10,9 | 63.314 ± 61.4 | 113.386 ± 36.9 | 175.739 ± 36.5 |
| Ae (6-8),n=10,10,9 | 54.631 ± 57.4 | 48.536 ± 93.3 | 70.582 ± 70.7 |
| Ae (8-12),n=10,10,9 | 35.322 ± 37.1 | 48.906 ± 41.0 | 47.392 ± 85.2 |
| Ae (12-24),n=10,10,9 | 14.201 ± 40.3 | 22.931 ± 65.9 | 36.214 ± 65.8 |
| Ae (24-36),n=10,10,9 | 6.510 ± 49.0 | 8.463 ± 55.4 | 12.642 ± 50.7 |
| Ae (36-48),n=10,10,8 | 3.265 ± 53.3 | 3.150 ± 71.5 | 5.641 ± 42.4 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Urine AUC (0-12) for Part 3 | 1573 ± 48.3 | 2812 ± 42.4 | 3517 ± 52.4 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Urine AUC (0-24) for Part 3 | 1879 ± 51.8 | 3301 ± 45.5 | 4197 ± 54.1 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| micrograms*hours/milliliter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| Urine AUC (0-48) for Part 3 | 2024 ± 54.3 | 3455 ± 46.6 | 4390 ± 54.1 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher.
| Percentage dose of drug excreted | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| fe% for Part 3 | 26.008 ± 34.3 | 27.273 ± 32.2 | 29.858 ± 27.8 |
PK urine samples were collected at pre-dose, 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48 hours. PK parameters were determined from the urine concentration- time data and were calculated by standard non-compartmental analysis according to current working practices and using Phoenix WinNonlin Version 6.2.1 or higher
| liters/hour | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed |
|---|---|---|---|
| CLr for Part 3 | 17.196 ± 24.8 | 16.598 ± 26.5 | 17.969 ± 21.2 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Participants with non-serious AEs and SAEs has been reported. Safety Population comprised of all participants who received at least 1 dose of study medication and had at least 1 post dose safety assessment.
| Participants | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Non serious AE | 8 | 5 | 9 |
| SAE | 0 | 0 | 0 |
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| millimoles/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Serum glucose, Day 3 (48 hour), n=26, 26, 26 | 0.010 ± 0.2837 | 0.049 ± 0.3253 | 0.094 ± 0.2699 |
| Serum glucose, Follow-up, n=8, 9, 9 | 0.099 ± 0.3911 | 0.304 ± 0.5180 | 0.381 ± 0.3850 |
| Serum calcium, Day 3 (48 hour), n=26, 26, 26 | 0.050 ± 0.0968 | 0.054 ± 0.0802 | 0.051 ± 0.0700 |
| Serum calcium, Follow-up, n=8, 9, 9 | 0.003 ± 0.0861 | -0.019 ± 0.0692 | -0.046 ± 0.0865 |
| Serum carbon dioxide, Day 3 (48 hour),n=26, 26, 26 | -0.2 ± 1.39 | -0.2 ± 1.22 | 0.0 ± 1.22 |
| Serum carbon dioxide, Follow-up, n=8, 9, 9 | -1.4 ± 1.19 | -1.7 ± 1.58 | -1.6 ± 1.33 |
| Serum chloride, Day 3 (48 hour),n=26, 26, 26 | -1.0 ± 1.78 | -1.1 ± 2.00 | -1.0 ± 2.27 |
| Serum chloride, Follow-up, n=8, 9, 9 | 1.3 ± 1.75 | 0.7 ± 1.32 | 1.6 ± 2.24 |
| Serum potassium, Day 3 (48 hour), n=26,26,26 | -0.06 ± 0.297 | -0.04 ± 0.270 | -0.06 ± 0.298 |
| Serum potassium, Follow-up, n=8,9,9, | -0.18 ± 0.306 | -0.09 ± 0.237 | -0.24 ± 0.371 |
| Serum sodium, Day 3 (48 hour), n=26,26,26 | -0.3 ± 1.70 | -0.7 ± 1.67 | -0.5 ± 1.98 |
| Serum sodium, Follow-up, n=8,9,9 | -1.0 ± 2.39 | -1.3 ± 2.35 | -0.6 ± 1.74 |
| Serum urea nitrogen, Day 3 (48 hour), n=26,26,26 | -0.250 ± 1.0929 | -0.307 ± 1.0021 | -0.332 ± 1.0598 |
| Serum urea nitrogen, Follow-up, n=8,9,9 | -0.043 ± 1.4732 | -0.354 ± 1.0294 | -0.223 ± 1.0126 |
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| International units/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Serum ALT, Day 3 (48 hour), n=26, 26, 26 | -1.1 ± 7.04 | -0.1 ± 7.30 | -0.3 ± 6.54 |
| Serum ALT, Follow-up, n=8, 9, 9 | -3.0 ± 10.76 | 0.1 ± 11.57 | 5.4 ± 5.05 |
| Serum AP, Day 3 (48 hour), n=26, 26, 26 | 7.7 ± 5.69 | 8.3 ± 5.40 | 9.0 ± 6.25 |
| Serum AP, Follow-up, n=8, 9, 9 | 2.6 ± 6.07 | 7.2 ± 7.71 | 7.4 ± 4.75 |
| Serum AST, Day 3 (48 hour),n=26, 26, 26 | -0.6 ± 4.11 | -0.2 ± 4.01 | -0.5 ± 3.99 |
| Serum AST, Follow-up, n=8, 9, 9 | -0.1 ± 4.94 | 1.7 ± 7.18 | 3.1 ± 4.40 |
| Serum CK, Day 3 (48 hour),n=26, 26, 26 | -28.7 ± 43.65 | -26.4 ± 47.32 | -30.2 ± 41.96 |
| Serum CK, Follow-up, n=8, 9, 9 | 8.0 ± 42.32 | 29.0 ± 107.27 | 13.2 ± 26.16 |
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| grams/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Serum albumin, Day 3 (48 hour), n=26, 26, 26 | 1.5 ± 2.27 | 1.8 ± 1.98 | 1.8 ± 2.36 |
| Serum albumin, Follow-up, n=8, 9, 9 | -0.3 ± 2.55 | -0.7 ± 1.87 | -0.6 ± 2.46 |
| Serum protein, Day 3 (48 hour), n=26, 26, 26 | 1.8 ± 4.68 | 1.9 ± 3.10 | 2.1 ± 3.98 |
| Serum protein, Follow-up, n=8, 9, 9 | -2.1 ± 4.29 | -2.6 ± 3.32 | -2.1 ± 4.43 |
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin, serum creatinine and serum direct bilirubin Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| micromoles/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Serum bilirubin, Day 3 (48 hour), n=26, 26, 26 | 2.08 ± 2.746 | 1.59 ± 3.511 | 1.98 ± 3.018 |
| Serum bilirubin, Follow-up, n=8, 9, 9 | 2.34 ± 3.608 | -1.08 ± 1.943 | -1.19 ± 4.431 |
| Serum creatinine, Day 3 (48 hour), n=26, 26, 26 | 1.49 ± 5.758 | 2.14 ± 6.793 | 2.31 ± 6.564 |
| Serum creatinine, Follow-up, n=8, 9, 9 | 4.86 ± 5.349 | 2.28 ± 9.930 | 3.93 ± 5.859 |
| Serum direct bilirubin, Day 3 (48 hour),n=26,26,26 | 0.25 ± 0.422 | 0.17 ± 0.528 | 0.18 ± 0.482 |
| Serum direct bilirubin, Follow-up, n=8, 9, 9 | 0.46 ± 0.707 | -0.14 ± 0.384 | -0.09 ± 0.677 |
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| 10^9 cells/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood basophils, Day 3 (48 hour), n=26, 26, 26 | 0.004 ± 0.0344 | 0.004 ± 0.0344 | -0.004 ± 0.0344 |
| Blood basophils, Follow-up, n=8, 9, 9 | 0.000 ± 0.0000 | 0.000 ± 0.0500 | 0.000 ± 0.0000 |
| Blood eosinophils, Day 3 (48 hour), n=26, 26, 26 | 0.008 ± 0.0688 | 0.008 ± 0.0935 | 0.004 ± 0.0958 |
| Blood eosinophils, Follow-up, n=8, 9, 9 | 0.025 ± 0.0463 | 0.044 ± 0.0527 | 0.033 ± 0.1323 |
| Blood leukocytes, Day 3 (48 hour),n=26, 26, 26 | -0.388 ± 0.7464 | -0.300 ± 0.6957 | -0.400 ± 0.6675 |
| Blood leukocytes, Follow-up, n=8, 9, 9 | -0.175 ± 0.4862 | 0.000 ± 1.2728 | -0.400 ± 0.3841 |
| Blood lymphocytes, Day 3 (48 hour),n=26, 26, 26 | -0.050 ± 0.2832 | 0.015 ± 0.3081 | -0.008 ± 0.4127 |
| Blood lymphocytes, Follow-up, n=8, 9, 9 | 0.025 ± 0.2866 | -0.100 ± 0.4444 | 0.011 ± 0.2147 |
| Blood monocytes, Day 3 (48 hour),n=26, 26, 26 | -0.065 ± 0.0977 | -0.069 ± 0.0970 | -0.096 ± 0.0871 |
| Blood monocytes, Follow-up, n=8, 9, 9 | 0.050 ± 0.0926 | 0.033 ± 0.1323 | -0.056 ± 0.0527 |
| Blood neutrophils, Day 3 (48 hour),n=26, 26, 26 | -0.254 ± 0.5907 | -0.238 ± 0.5845 | -0.288 ± 0.4702 |
| Blood neutrophils, Follow-up, n=8, 9, 9 | -0.213 ± 0.5330 | 0.089 ± 0.7976 | -0.356 ± 0.4187 |
| Blood platelets, Day 3 (48 hour),n=26, 26, 26 | 11.5 ± 14.76 | 17.4 ± 16.43 | 14.5 ± 17.85 |
| Blood platelets, Follow-up, n=8, 9, 9 | 3.8 ± 17.90 | 1.8 ± 17.89 | 9.8 ± 26.48 |
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| grams/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood Ery. MCHC, Day 3 (48 hour), n=26, 26, 26 | 0.4 ± 4.78 | 0.9 ± 4.27 | 0.4 ± 5.56 |
| Blood Ery. MCHC, Follow-up, n=8, 9, 9 | 2.5 ± 6.63 | 4.1 ± 3.33 | 3.0 ± 5.52 |
| Blood hemoglobin, Day 3 (48 hour), n=26, 26, 26 | 8.0 ± 7.21 | 8.5 ± 6.59 | 8.4 ± 7.26 |
| Blood hemoglobin, Follow-up, n=8, 9, 9 | -3.8 ± 6.45 | -4.4 ± 6.29 | -2.3 ± 8.03 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| picograms | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood Ery.MCH, Day 3 (48 hour), n=26, 26, 26 | -0.03 ± 0.360 | 0.00 ± 0.280 | -0.02 ± 0.400 |
| Blood Ery. MCH, Follow-up, n=8, 9, 9 | -0.03 ± 0.512 | 0.14 ± 0.270 | 0.04 ± 0.317 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| femtoliters | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood Ery. MCV, Day 3 (48 hour), n=26, 26, 26 | -0.21 ± 0.471 | -0.26 ± 0.568 | -0.23 ± 0.586 |
| Blood Ery. MCV, Follow-up, n=8, 9, 9 | -0.73 ± 0.618 | -0.58 ± 0.549 | -0.72 ± 0.800 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| 10^12 cells/liter | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood Ery. , Day 3 (48 hour), n=26, 26, 26 | 0.279 ± 0.2597 | 0.293 ± 0.2450 | 0.296 ± 0.2538 |
| Blood Ery. , Follow-up, n=8, 9, 9 | -0.130 ± 0.2045 | -0.190 ± 0.2258 | -0.101 ± 0.2538 |
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| Percentage of red blood cells in blood | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Blood hematocrit , Day 3 (48 hour), n=26, 26, 26 | 2.32 ± 2.212 | 2.43 ± 2.110 | 2.48 ± 2.200 |
| Blood hematocrit, Follow-up, n=8, 9, 9 | -1.50 ± 1.628 | -1.87 ± 1.781 | -1.20 ± 2.029 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| millimeters of mercury | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| SBP, Day 1 (2 hours), n=26, 26, 26, | 1.8 ± 6.88 | -1.3 ± 7.24 | 1.1 ± 5.25 |
| SBP, Day 2 (24 hours), n=26, 26, 26 | 0.1 ± 6.82 | -2.8 ± 10.21 | -1.8 ± 5.31 |
| SBP, Day 3 (48 hours), n=26, 26, 26 | 5.3 ± 7.93 | -1.3 ± 7.12 | -0.2 ± 6.46 |
| SBP, Follow-up, n=8,9,9 | 18.0 ± 11.28 | 9.4 ± 6.09 | 6.9 ± 7.83 |
| DBP, Day 1 (2 hours), n=26, 26, 26, | 3.2 ± 7.04 | 1.0 ± 5.59 | 2.2 ± 6.34 |
| DBP, Day 2 (24 hours), n=26, 26, 26 | 2.3 ± 8.11 | -0.4 ± 7.41 | 0.0 ± 6.87 |
| DBP, Day 3 (48 hours), n=26, 26, 26 | 2.2 ± 7.65 | 2.8 ± 6.29 | 1.0 ± 7.19 |
| DBP, Follow-up, n=8,9,9 | 8.3 ± 7.36 | 6.4 ± 5.73 | 7.4 ± 4.85 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| beats/minute | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Heart rate, Day 1 (2 hours), n=26, 26, 26, | -0.7 ± 7.59 | 0.0 ± 4.61 | 1.7 ± 3.61 |
| Heart rate, Day 2 (24 hours), n=26, 26, 26 | -0.7 ± 7.11 | 0.6 ± 5.87 | 1.7 ± 3.82 |
| Heart rate, Day 3 (48 hours), n=26, 26, 26 | -0.2 ± 8.18 | -0.2 ± 6.20 | 3.2 ± 5.46 |
| Heart rate, Follow-up, n=8,9,9 | -0.1 ± 3.04 | 0.2 ± 7.56 | 5.7 ± 5.15 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| beats per minute | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| ECG Heart rate, Day 1 (2 hours), n=26, 26, 26, | -1.1 ± 6.33 | -1.0 ± 6.05 | 0.4 ± 3.60 |
| ECG Heart rate, Day 2 (24 hours), n=26, 26, 26 | 0.2 ± 5.85 | -0.4 ± 8.02 | 0.3 ± 3.96 |
| ECG Heart rate, Day 3 (48 hours), n=26, 26, 26 | 0.0 ± 6.39 | -0.6 ± 7.00 | 1.0 ± 4.04 |
| ECG Heart rate, Follow-up, n=8,9,9 | -1.0 ± 4.11 | 0.7 ± 8.82 | 3.6 ± 6.56 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 1a. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles).
| milliseconds | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| PR interval, Day 1 (2 hours), n=26, 26, 26 | -2.5 ± 12.28 | -3.2 ± 11.79 | -3.8 ± 6.01 |
| PR interval, Day 2 (24 hours), n=26, 26, 26 | 1.7 ± 13.77 | -0.1 ± 8.80 | -0.5 ± 9.20 |
| PR interval,, Day 3 (48 hours), n=26, 26, 26 | 1.2 ± 9.64 | -0.3 ± 7.74 | 2.0 ± 12.51 |
| PR interval, Follow-up, n=8,9,9 | 4.0 ± 14.89 | -3.1 ± 9.98 | -9.2 ± 7.41 |
| QRS duration, Day 1 (2 hours), n=26, 26, 26, | 1.3 ± 4.65 | 0.1 ± 5.61 | -0.4 ± 4.64 |
| QRS duration, Day 2 (24 hours), n=26, 26, 26 | 0.3 ± 3.64 | -1.0 ± 5.62 | -0.5 ± 5.07 |
| QRS duration, Day 3 (48 hours), n=26, 26, 26 | 0.1 ± 4.47 | -0.1 ± 5.42 | -1.8 ± 5.28 |
| QRS duration, Follow-up, n=8,9,9 | -0.4 ± 7.21 | 2.1 ± 8.31 | 0.9 ± 2.26 |
| QT interval Day 1 (2 hours), n=26, 26, 26, | 9.6 ± 14.42 | 6.4 ± 12.07 | 8.8 ± 11.28 |
| QT interval, Day 2 (24 hours), n=26, 26, 26 | 1.5 ± 11.55 | 2.1 ± 15.22 | 2.4 ± 8.40 |
| QT interval, Day 3 (48 hours), n=26, 26, 26 | 1.8 ± 12.95 | -0.5 ± 14.55 | -0.7 ± 10.80 |
| QT interval, Follow-up, n=8,9,9 | 17.5 ± 22.99 | 5.2 ± 29.79 | -3.6 ± 17.81 |
| QTcB interval, Day 1 (2 hours), n=26, 26, 26, | 6.6 ± 14.07 | 4.3 ± 14.96 | 10.3 ± 11.26 |
| QTcB, Day 2 (24 hours), n=26, 26, 26 | 1.8 ± 12.63 | 1.7 ± 13.74 | 3.8 ± 9.86 |
| QTcB, Day 3 (48 hours), n=26, 26, 26 | 2.0 ± 12.56 | -1.6 ± 13.26 | 2.9 ± 9.76 |
| QTcB, Follow-up, n=8,9,9 | 13.9 ± 19.95 | 2.9 ± 19.62 | 6.0 ± 11.51 |
| QTcF interval, Day 1 (2 hours), n=26, 26, 26, | 7.5 ± 10.56 | 4.8 ± 11.05 | 10.0 ± 9.57 |
| QTcF, Day 2 (24 hours), n=26, 26, 26 | 1.7 ± 9.11 | 2.0 ± 9.73 | 3.4 ± 7.21 |
| QTcF, Day 3 (48 hours), n=26, 26, 26 | 2.0 ± 8.30 | -1.3 ± 9.93 | 1.8 ± 8.20 |
| QTcF, Follow-up, n=8,9,9 | 15.4 ± 20.16 | 4.9 ± 18.84 | 4.6 ± 7.65 |
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 1a. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets |
|---|---|---|---|
| Urine Ketones, Day 3 (48 hours), 1+ | 1 | 0 | 0 |
| Urine pH, Day 3 (48 hours), 5+ | 4 | 4 | 4 |
| Urine pH, Day 3 (48 hours), 6+ | 18 | 16 | 14 |
| Urine pH, Day 3 (48 hours), 7+ | 3 | 6 | 8 |
| Urine pH, Day 3 (48 hours), 8+ | 1 | 0 | 0 |
| Urine pH, Follow-up, 5+ | 2 | 4 | 3 |
| Urine pH, Follow-up, 6+ | 5 | 5 | 4 |
| Urine pH, Follow-up, 7+ | 1 | 0 | 2 |
| Urine Specific gravity, Day 3 (48 hours), 1+ | 26 | 26 | 26 |
| Urine Specific gravity, Follow-up, 1+ | 8 | 9 | 9 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of chemistry parameters namely serum albuim and serum protein for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 1b. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 1b. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Since the relative bio-availability of the RC tablet formulation under fasted and fed conditions had been previously evaluated in Study BTZ117349 (NCT02045849), Part 1b was not conducted.
No measurements were reported for this outcome.
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
| Participants | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Non serious AE | 6 | 9 |
| SAE | 0 | 0 |
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| millimoles/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Serum glucose, Day 3 (48 hour) | -0.146 ± 0.4421 | -0.133 ± 0.3665 |
| Serum glucose, Follow-up | NA ± NA | -0.211 ± 0.5005 |
| Serum calcium, Day 3 (48 hour) | -0.027 ± 0.1055 | -0.009 ± 0.0684 |
| Serum calcium, Follow-up | NA ± NA | -0.011 ± 0.0638 |
| Serum carbon dioxide, Day 3 (48 hour) | 1.5 ± 1.96 | -1.4 ± 1.71 |
| Serum carbon dioxide, Follow-up | NA ± NA | -0.4 ± 1.78 |
| Serum chloride, Day 3 (48 hour) | -1.5 ± 1.96 | -1.2 ± 2.04 |
| Serum chloride, Follow-up | NA ± NA | 0.1 ± 2.13 |
| Serum potassium, Day 3 (48 hour) | -0.03 ± 0.437 | -0.16 ± 0.517 |
| Serum potassium, Follow-up | NA ± NA | 0.01 ± 0.446 |
| Serum sodium, Day 3 (48 hour) | -1.1 ± 1.45 | -0.9 ± 2.02 |
| Serum sodium, Follow-up | NA ± NA | 0.4 ± 2.22 |
| Serum urea nitrogen, Day 3 (48 hour) | 0.678 ± 0.8489 | 1.321 ± 1.2692 |
| Serum urea nitrogen, Follow-up | NA ± NA | 0.216 ± 1.7478 |
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| International units/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Serum ALT, Day 3 (48 hour) | -0.2 ± 1.55 | 1.3 ± 3.16 |
| Serum ALT, Follow-up | NA ± NA | 3.1 ± 5.95 |
| Serum AP, Day 3 (48 hour) | -0.3 ± 5.44 | -0.3 ± 4.00 |
| Serum AP, Follow-up | NA ± NA | -1.7 ± 2.95 |
| Serum AST, Day 3 (48 hour) | 0.5 ± 2.92 | 1.0 ± 2.71 |
| Serum AST, Follow-up | NA ± NA | 3.5 ± 4.81 |
| Serum CK, Day 3 (48 hour) | -22.7 ± 26.45 | -25.7 ± 15.81 |
| Serum CK, Follow-up | NA ± NA | -9.8 ± 13.99 |
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose-visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| grams/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Serum albumin, Day 3 (48 hour) | -0.9 ± 3.38 | 0.0 ± 1.70 |
| Serum albumin, Follow-up | NA ± NA | -1.5 ± 2.17 |
| Serum protein, Day 3 (48 hour) | 0.0 ± 5.29 | -2.1 ± 4.63 |
| Serum protein, Follow-up, | NA ± NA | -1.8 ± 2.70 |
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin, serum creatinine and serum direct bilirubin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| micromoles/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Serum bilirubin, Day 3 (48 hour) | -1.02 ± 2.944 | -3.62 ± 2.968 |
| Serum bilirubin | NA ± NA | -0.68 ± 4.207 |
| Serum creatinine, Day 3 (48 hour) | -1.76 ± 8.147 | -4.42 ± 6.254 |
| Serum creatinine | NA ± NA | -3.55 ± 7.458 |
| Serum direct bilirubin, Day 3 (48 hour) | -0.51 ± 1.147 | -1.02 ± 0.878 |
| Serum direct bilirubin, Follow-up | NA ± NA | -0.34 ± 1.075 |
Blood samples were collected for the assessment of chemistry parameter namely serum estradiol for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the indicated time point were analyzed. NA indicates standard deviation was not calculated as a single participant was analyzed.
| picomoles/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Change From Baseline in Clinical Chemistry Parameter Serum Estradiol for Part 2 | NA ± NA | 0.00 ± NA |
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| 10^9 cells/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood basophils, Day 3 (48 hour) | 0.002 ± 0.0092 | 0.009 ± 0.0129 |
| Blood basophils, Follow-up | NA ± NA | 0.004 ± 0.0097 |
| Blood eosinophils, Day 3 (48 hour) | 0.036 ± 0.0626 | 0.052 ± 0.0839 |
| Blood eosinophils, Follow-up | NA ± NA | 0.021 ± 0.0671 |
| Blood leukocytes, Day 3 (48 hour) | 0.129 ± 0.7779 | 0.039 ± 0.8843 |
| Blood leukocytes, Follow-up | NA ± NA | -0.183 ± 0.7906 |
| Blood lymphocytes, Day 3 (48 hour) | 0.222 ± 0.1707 | 0.243 ± 0.2165 |
| Blood lymphocytes, Follow-up | NA ± NA | -0.038 ± 0.2875 |
| Blood monocytes, Day 3 (48 hour) | -0.020 ± 0.0651 | -0.013 ± 0.0732 |
| Blood monocytes, Follow-up | NA ± NA | 0.045 ± 0.0546 |
| Blood neutrophils, Day 3 (48 hour) | -0.112 ± 0.6906 | -0.251 ± 0.6701 |
| Blood neutrophils, Follow-up | NA ± NA | -0.213 ± 0.8126 |
| Blood platelets, Day 3 (48 hour) | -7.4 ± 38.14 | -0.6 ± 33.37 |
| Blood platelets, Follow-up | NA ± NA | 2.1 ± 31.49 |
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| grams/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood Ery. MCHC, Day 3 (48 hour) | -6.6 ± 4.35 | -6.6 ± 3.20 |
| Blood Ery. MCHC, Follow-up | NA ± NA | -6.2 ± 5.87 |
| Blood hemoglobin, Day 3 (48 hour) | 2.8 ± 9.43 | 0.9 ± 5.55 |
| Blood hemoglobin, Follow-up | NA ± NA | -5.9 ± 3.67 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| picograms | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood Ery.MCH, Day 3 (48 hour) | -0.25 ± 0.331 | -0.06 ± 0.378 |
| Blood Ery. MCH, Follow-up | NA ± NA | -0.15 ± 0.488 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| femtoliters | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood Ery. MCV, Day 3 (48 hour) | 1.17 ± 1.610 | 1.69 ± 1.371 |
| Blood Ery. MCV, Follow-up | NA ± NA | 1.28 ± 1.834 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| 10^12 cells/liter | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood Ery., Day 3 (48 hour) | 0.118 ± 0.2839 | 0.033 ± 0.1675 |
| Blood Ery., Follow-up | NA ± NA | -0.175 ± 0.1099 |
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 2. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| Percentage of red blood cells in blood | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Blood hematocrit , Day 3 (48 hour) | 1.6 ± 2.871 | 1.02 ± 1.713 |
| Blood hematocrit, Follow-up | NA ± NA | -1.09 ± 1.079 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| millimeters of mercury | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| SBP, Day 1 (2 hours) | -8.4 ± 15.78 | 6.7 ± 10.49 |
| SBP, Day 2 (24 hours) | -9.6 ± 13.55 | -3.1 ± 12.90 |
| SBP, Day 3 (48 hours) | -4.1 ± 17.99 | -4.2 ± 11.03 |
| SBP, Follow-up | NA ± NA | -2.0 ± 17.81 |
| DBP, Day 1 (2 hours) | -6.7 ± 6.13 | -0.3 ± 6.95 |
| DBP, Day 2 (24 hours) | -5.4 ± 8.72 | -3.5 ± 6.92 |
| DBP, Day 3 (48 hours) | -1.9 ± 7.98 | -1.7 ± 6.62 |
| DBP, Follow-up | NA ± NA | -0.1 ± 11.35 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| beats/minute | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Heart rate, Day 1 (2 hours) | 0.1 ± 7.84 | 3.2 ± 6.48 |
| Heart rate, Day 2 (24 hours) | -3.8 ± 12.38 | -1.4 ± 6.90 |
| Heart rate, Day 3 (48 hours) | -3.0 ± 11.22 | 3.4 ± 6.29 |
| Heart rate, Follow-up | NA ± NA | -0.3 ± 9.06 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| beats/minute | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| ECG Heart rate, Day 1 (2 hours) | 5.4 ± 10.13 | 4.9 ± 5.02 |
| ECG Heart rate, Day 2 (24 hours) | -1.2 ± 8.75 | -1.1 ± 6.71 |
| ECG Heart rate, Day 3 (48 hours) | 2.1 ± 11.00 | 3.4 ± 5.38 |
| ECG Heart rate, Follow-up | NA ± NA | -1.6 ± 8.18 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 2. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. NA indicates participants crossed-over as follow-up visit occurred after Period 2.
| milliseconds | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| PR interval, Day 1 (2 hours) | -1.7 ± 13.92 | 0.5 ± 11.49 |
| PR interval, Day 2 (24 hours) | 7.2 ± 11.44 | -2.7 ± 7.23 |
| PR interval, Day 3 (48 hours) | 5.1 ± 11.46 | 3.0 ± 11.71 |
| PR interval, Follow-up | NA ± NA | -1.2 ± 15.37 |
| QRS duration, Day 1 (2 hours) | 0.4 ± 5.19 | 3.9 ± 4.28 |
| QRS duration, Day 2 (24 hours) | 0.3 ± 4.57 | -0.2 ± 4.73 |
| QRS duration, Day 3 (48 hours) | -0.2 ± 4.54 | 0.7 ± 4.06 |
| QRS duration, Follow-up | NA ± NA | 1.6 ± 3.60 |
| QT interval Day 1 (2 hours) | -4.0 ± 16.21 | 5.1 ± 16.04 |
| QT interval, Day 2 (24 hours) | 4.8 ± 21.63 | 11.7 ± 17.31 |
| QT interval, Day 3 (48 hours) | -1.0 ± 20.48 | -3.4 ± 14.95 |
| QT interval, Follow-up | NA ± NA | 9.5 ± 17.37 |
| QTcB interval, Day 1 (2 hours) | 15.2 ± 18.23 | 20.7 ± 14.17 |
| QTcB, Day 2 (24 hours) | 3.4 ± 11.64 | 9.5 ± 8.24 |
| QTcB, Day 3 (48 hours) | 6.6 ± 16.26 | 6.0 ± 13.00 |
| QTcB, Follow-up | NA ± NA | 5.7 ± 13.44 |
| QTcF interval, Day 1 (2 hours) | 8.6 ± 9.56 | 15.2 ± 13.09 |
| QTcF, Day 2 (24 hours) | 4.0 ± 10.23 | 10.4 ± 8.75 |
| QTcF, Day 3 (48 hours) | 4.0 ± 8.60 | 2.4 ± 11.64 |
| QTcF, Follow-up | NA ± NA | 7.0 ± 9.36 |
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 4+ 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 2. Only categories with significant values have been presented.
| Participants | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets |
|---|---|---|
| Urine Ketones, Follow-up, Trace | 0 | 1 |
| Urine Occult blood, Day 3 (48 hours), 1+ | 0 | 1 |
| Urine Occult blood, Trace, Day 3 (48 hours), | 2 | 0 |
| Urine Occult blood, Follow-up, 1+ | 0 | 1 |
| Urine pH, Day 3 (48 hours), 5+ | 2 | 7 |
| Urine pH, Day 3 (48 hours), 6+ | 6 | 2 |
| Urine pH, Day 3 (48 hours), 7+ | 1 | 1 |
| Urine pH, Day 3 (48 hours), 8+ | 1 | 0 |
| Urine pH, Follow-up, 5+ | 0 | 3 |
| Urine pH, Follow-up, 6+ | 0 | 6 |
| Urine pH, Follow-up, 8+ | 0 | 1 |
| Urine Specific gravity, Day 3 (48 hours), 1+ | 10 | 10 |
| Urine Specific gravity, Follow-up, 1+ | 0 | 10 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.
| Participants | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Non seriou AE | 0 | 1 | 6 | 0 |
| SAE | 0 | 0 | 0 | 0 |
Blood samples were collected for the assessment of chemistry parameters namely serum glucose, serum calcium, serum carbon dioxide, serum chloride, serum potassium, serum sodium and serum urea nitrogen for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| millimoles/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Glucose,Period 1,Day 3(48 hour),n=10,0,0,2 | 0.038 ± 0.3178 | — | — | -0.305 ± 0.4313 |
| Glucose,Period 2,Day 3 (48 hour),n=0,10,0,2 | — | -0.071 ± 0.2993 | — | -0.415 ± 0.2758 |
| Glucose,Period 3,Day 3 (48 hour),n=0,0,9,2 | — | — | -0.197 ± 0.2355 | -0.335 ± 0.1626 |
| Glucose, Follow-up, n=0,0,9,2 | — | — | -0.050 ± 0.2744 | -0.390 ± 0.3960 |
| Calcium,Period1, Day 3 (48 hour),n=10,0,0,2 | -0.057 ± 0.0887 | — | — | -0.075 ± 0.1061 |
| Calcium,Period 2,Day 3 (48 hour),n=0,10,0,2 | — | -0.046 ± 0.0819 | — | -0.115 ± 0.0919 |
| Calcium,Period 3,Day 3 (48 hour),n=0,0,9,2 | — | — | -0.028 ± 0.0502 | -0.105 ± 0.0354 |
| Calcium, Follow-up, n=0,0, 9, 2 | — | — | -0.039 ± 0.0742 | -0.040 ± 0.0141 |
| Carbon dioxide,Period 1,Day 3(48 hour),n=10,0,0,2 | -0.6 ± 1.51 | — | — | 0.5 ± 0.71 |
| Carbon dioxide,Period 2,Day 3(48 hour),n=0,10,0,2 | — | -0.7 ± 1.64 | — | 2.5 ± 2.12 |
| Carbon dioxide,Period 3,Day 3(48 hour),n=0,0,9,2 | — | — | -1.1 ± 1.36 | 1.5 ± 0.71 |
| Carbon dioxide, Follow-up, n=0,0,9,2 | — | — | 0.2 ± 2.28 | 1.5 ± 0.71 |
| Chloride, Period 1, Day 3 (48 hour),n=10,0,0,2 | 0.8 ± 1.23 | — | — | 1.0 ± 2.83 |
| Chloride, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | 0.8 ± 1.75 | — | -2.0 ± 0.00 |
| Chloride, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | 0.1 ± 1.96 | -1.5 ± 0.71 |
| Chloride, Follow-up,n=0,0,9,2 | — | — | 0.2 ± 2.95 | -2.0 ± 0.00 |
| Potassium, Period 1, Day 3 (48 hour), n=10,0,0,2 | -0.21 ± 0.536 | — | — | -0.10 ± 0.283 |
| Potassium, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -0.19 ± 0.381 | — | -0.40 ± 1.131 |
| Potassium, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -0.28 ± 0.561 | -0.30 ± 1.273 |
| Potassium, Follow-up, n=0,0,9,2 | — | — | -0.21 ± 0.359 | -0.15 ± 0.919 |
| Sodium, Period 1, Day 3 (48 hour), n=10,0,0,2 | 0.6 ± 2.12 | — | — | 2.5 ± 2.12 |
| Sodium, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | 0.1 ± 2.38 | — | -1.0 ± 2.83 |
| Sodium, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | 0.3 ± 1.94 | -2.0 ± 4.24 |
| Sodium, Follow-up, n=0,0,9,2 | — | — | -0.1 ± 1.90 | -2.5 ± 2.12 |
| Urea nitrogen,Period 1,Day 3 (48 hour),n=10,0,0,2 | 0.606 ± 1.0760 | — | — | 0.535 ± 0.2475 |
| Urea nitrogen,Period 2,Day 3 (48 hour),n=0,10,0,2 | — | 0.677 ± 1.3401 | — | 1.610 ± 0.7637 |
| Urea nitrogen,Period 3,Day 3 (48 hour),n=0,0,9,2 | — | — | 0.474 ± 1.4617 | 1.075 ± 0.0071 |
| Urea nitrogen, Follow-up, n=0,0,9,2 | — | — | 0.356 ± 1.2998 | 2.320 ± 2.7860 |
Blood samples were collected for the assessment of chemistry parameters namely serum ALT, serum AP, serum AST and serum CK for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| International units/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| ALT, Period 1, Day 3 (48 hour), n=10,0,0,2 | 0.1 ± 2.73 | — | — | -2.5 ± 2.12 |
| ALT, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | 2.2 ± 3.36 | — | -4.0 ± 7.07 |
| ALT, Period 3, Day 3 (48 hour), n=0,0,9,2, | — | — | 6.0 ± 3.74 | -4.5 ± 9.19 |
| ALT, Follow-up, n=0,0,9,2 | — | — | 5.9 ± 4.11 | -5.0 ± 11.31 |
| AP, Period 1, Day 3 (48 hour), n=10,0,0,2, | -3.6 ± 2.07 | — | — | -9.0 ± 5.66 |
| AP, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -2.5 ± 4.62 | — | -2.0 ± 4.24 |
| Serum AP, Day 3 (48 hour), n=0,0,9,2 | — | — | 0.6 ± 3.88 | -0.5 ± 0.71 |
| AP, Follow-up, n=0,0,9,2 | — | — | 1.8 ± 3.96 | 3.5 ± 3.54 |
| AST, Period 1, Day 3 (48 hour),n=10,0,0,2 | 1.3 ± 3.06 | — | — | -3.5 ± 2.12 |
| AST, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | 1.7 ± 2.50 | — | -5.0 ± 4.24 |
| AST, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | 4.2 ± 2.68 | -5.0 ± 5.66 |
| AST, Follow-up, n=0,0,9,2 | — | — | 2.6 ± 2.46 | -4.0 ± 7.07 |
| CK, Period 1, Day 3 (48 hour),n=10,0,0,2 | -28.1 ± 17.60 | — | — | -22.5 ± 14.85 |
| CK, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | -11.8 ± 65.84 | — | -33.5 ± 23.33 |
| CK, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | -14.3 ± 20.27 | -21.5 ± 9.19 |
| CK, Follow-up, n=0,0,9,2 | — | — | 3.7 ± 26.87 | 1.0 ± 11.31 |
Blood samples were collected for the assessment of chemistry parameters namely serum albumin and serum protein for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| grams/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Albumin, Part 1, Day 3 (48 hour), n=10,0,0,2 | -2.0 ± 2.54 | — | — | -2.0 ± 0.00 |
| Albumin, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -2.0 ± 1.05 | — | -3.0 ± 1.41 |
| Albumin, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -0.6 ± 3.05 | -2.5 ± 0.71 |
| Albumin, Follow-up, n=0,0,9,2 | — | — | -0.3 ± 3.12 | -0.5 ± 2.12 |
| Protein, Period 1, Day 3 (48 hour), n=10,0,0,2 | -3.0 ± 2.31 | — | — | -4.5 ± 0.71 |
| Protein, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -2.2 ± 3.01 | — | -5.0 ± 1.41 |
| Protein, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -0.6 ± 3.97 | -4.5 ± 0.71 |
| Protein, Follow-up, n=0,0,9,2 | — | — | -0.6 ± 4.64 | -1.0 ± 5.66 |
Blood samples were collected for the assessment of chemistry parameters namely serum bilirubin and serum creatinine for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm
| micromoles/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Bilirubin, Period 1, Day 3 (48 hour), n=10,0,0,2 | -2.43 ± 3.364 | — | — | -0.85 ± 1.202 |
| Bilirubin, Period 2, Day 3 (48 hour), n=0,10,0,2, | — | -3.11 ± 3.793 | — | -1.70 ± 0.000 |
| Bilirubin, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -2.28 ± 3.844 | 0.85 ± 1.202 |
| Bilirubin, Follow-up, n=0,0,9,2 | — | — | -1.53 ± 2.757 | -1.70 ± 0.000 |
| Creatinine, Period 1,Day 3 (48 hour), n=10,0,0,2 | -1.75 ± 8.101 | — | — | -17.65 ± 12.516 |
| Creatinine, Period 2,Day 3 (48 hour), n=0,10,0,2 | — | -1.75 ± 6.958 | — | -17.60 ± 0.000 |
| Creatinine, Period 3,Day 3 (48 hour), n=0,0,9,2 | — | — | 0.01 ± 7.636 | -13.20 ± 6.223 |
| Creatinine, Follow-up, n=0,0,9,2 | — | — | 2.97 ± 6.258 | -4.40 ± 6.223 |
Blood samples were collected for the assessment of hematology parameters namely blood basophils, blood eosinophils, blood leukocytes, blood lymphocytes, blood monocytes, blood neutrophils and blood platelets for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| 10^9 cells/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Basophils, Period 1, Day 3 (48 hour), n=10,0,0,2 | 0.004 ± 0.0158 | — | — | 0.000 ± 0.0141 |
| Basophils, Period 2, Day 3 (48 hour), n=0,10,0,2, | — | 0.009 ± 0.0120 | — | -0.010 ± 0.0141 |
| Basophils, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | 0.009 ± 0.0162 | 0.005 ± 0.0071 |
| Basophils, Follow-up, n=0,0,9,2 | — | — | 0.008 ± 0.0186 | 0.015 ± 0.0071 |
| Eosinophils, Period 1, Day 3 (48 hour),n=10,0,0,2 | 0.053 ± 0.0254 | — | — | 0.060 ± 0.0707 |
| Eosinophils, Period 2,Day 3 (48 hour), n=0,10,0,2 | — | 0.068 ± 0.0421 | — | 0.055 ± 0.0778 |
| Eosinophils, Period 3,Day 3 (48 hour), n=0,0,9,2 | — | — | 0.053 ± 0.0487 | 0.040 ± 0.0990 |
| Eosinophils, Follow-up, n=0,0,9,2 | — | — | 0.022 ± 0.0192 | 0.045 ± 0.1061 |
| Leukocytes, Period 1, Day 3 (48 hour),n=10,0,0,2 | 0.581 ± 0.6524 | — | — | -1.000 ± 0.8202 |
| Leukocytes, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | 0.730 ± 0.8427 | — | -1.415 ± 1.0819 |
| Leukocytes, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | 0.966 ± 0.7001 | -1.670 ± 0.9475 |
| Leukocytes, Follow-up, n=0,0,9,2 | — | — | 0.132 ± 0.8490 | -1.630 ± 0.2121 |
| Lymphocytes, Period 1,Day 3 (48 hour),n=10,0,0,2 | 0.209 ± 0.2885 | — | — | 0.060 ± 0.2263 |
| Lymphocytes, Period 2,Day 3 (48 hour),n=0,10,0,2 | — | 0.144 ± 0.3405 | — | -0.035 ± 0.2192 |
| Lymphocytes, Period 3,Day 3 (48 hour),n=0,0,9,2 | — | — | -0.009 ± 0.3207 | -0.100 ± 0.2404 |
| Lymphocytes, Follow-up, n=0,0, 9, 2 | — | — | -0.089 ± 0.1928 | -0.050 ± 0.0283 |
| Monocytes, Period 1, Day 3 (48 hour),n=10,0,0,2, | 0.022 ± 0.0598 | — | — | -0.025 ± 0.0354 |
| Monocytes, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | 0.010 ± 0.0615 | — | -0.080 ± 0.0424 |
| Monocytes, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | 0.042 ± 0.0427 | -0.110 ± 0.0000 |
| Monocytes, Follow-up, n=0,0,9,2 | — | — | -0.002 ± 0.0452 | -0.100 ± 0.0424 |
| Neutrophils, Period 1,Day 3 (48 hour),n=10,0,0,2 | 0.292 ± 0.8198 | — | — | -1.100 ± 1.1597 |
| Neutrophils, Period 2,Day 3 (48 hour),n=0,10,0,2 | — | 0.489 ± 0.7302 | — | -1.350 ± 0.8910 |
| Neutrophils, Period 3,Day 3 (48 hour),n=0,0,9,2 | — | — | 0.850 ± 0.8456 | -1.505 ± 0.7990 |
| Neutrophils, Follow-up, n=0,0,9,2 | — | — | 0.184 ± 0.8251 | -1.545 ± 0.3606 |
| Platelets, Period 1, Day 3 (48 hour),n=10,0,0,2 | -4.7 ± 13.19 | — | — | -10.5 ± 10.61 |
| Platelets, Period 2, Day 3 (48 hour),n=0,10,0,2 | — | -22.2 ± 41.82 | — | -5.0 ± 5.66 |
| Platelets, Period 3, Day 3 (48 hour),n=0,0,9,2 | — | — | -6.0 ± 19.80 | -15.0 ± 8.49 |
| Platelets, Follow-up, n=0,0,9,2 | — | — | 2.4 ± 21.93 | 4.0 ± 8.49 |
Blood samples were collected for the assessment of hematology parameters namely blood Ery. MCHC and blood hemoglobin for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| grams/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Ery. MCHC, Period 1, Day 3 (48 hour), n=10,0,0,2 | -2.9 ± 5.67 | — | — | -2.0 ± 9.90 |
| Ery. MCHC, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -3.2 ± 3.49 | — | -1.5 ± 4.95 |
| Ery. MCHC, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -5.3 ± 5.22 | -6.5 ± 2.12 |
| Ery. MCHC, Follow-up, n=0,0,9,2 | — | — | -1.2 ± 4.94 | 0.0 ± 0.00 |
| Hemoglobin, Period 1,Day 3 (48 hour), n=10,0,0,2 | -1.4 ± 6.70 | — | — | -7.5 ± 0.71 |
| Hemoglobin, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -3.4 ± 9.35 | — | -11.5 ± 0.71 |
| Hemoglobin, Period 3,Day 3 (48 hour), n=0,0,9,2 | — | — | -2.1 ± 6.47 | -10.5 ± 0.71 |
| Hemoglobin, Follow-up, n=0,0,9,2 | — | — | -6.0 ± 7.62 | -6.5 ± 7.78 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCH for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| picograms | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Ery.MCH, Period 1, Day 3 (48 hour), n=10,0,0,2 | 0.08 ± 0.397 | — | — | 0.25 ± 0.071 |
| Ery.MCH, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | 0.08 ± 0.270 | — | 0.15 ± 0.212 |
| Ery.MCH, Period 3 Day 3 (48 hour), n=0,0,9,2 | — | — | -0.12 ± 0.380 | 0.00 ± 0.283 |
| Ery. MCH, Follow-up, n=0,0,9,2 | — | — | 0.31 ± 0.483 | 0.00 ± 0.424 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. MCV for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| femtoliters | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Ery. MCV, Period 1, Day 3 (48 hour), n=10,0,0,2 | 1.10 ± 1.152 | — | — | 1.30 ± 2.970 |
| Ery. MCV, Period 2, Day 3 (48 hour), n=0,10,0,2 | — | 1.14 ± 0.857 | — | 0.70 ± 2.121 |
| Ery. MCV, Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | 1.16 ± 1.167 | 1.80 ± 0.000 |
| Ery. MCV, Follow-up, n=0,0,9,2 | — | — | 1.31 ± 1.430 | 0.00 ± 1.131 |
Blood samples were collected for the assessment of hematology parameter namely blood Ery. for Part 1a. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| 10^12 cells/liter | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Ery., Period 1, Day 3 (48 hour), n=10,0,0,2 | -0.065 ± 0.2576 | — | — | -0.275 ± 0.0354 |
| Ery.,Period 2, Day 3 (48 hour), n=0,10,0,2 | — | -0.138 ± 0.3381 | — | -0.390 ± 0.0566 |
| Ery., Period 3, Day 3 (48 hour), n=0,0,9,2 | — | — | -0.060 ± 0.2536 | -0.340 ± 0.0566 |
| Ery., Follow-up, n=0,0,9,2 | — | — | -0.253 ± 0.3347 | -0.210 ± 0.3111 |
Blood samples were collected for the assessment of hematology parameter namely blood hematocrit for Part 3. Baseline was defined as assessments performed on Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| Percentage of red blood cells in blood | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Hematocrit, Period 1,Day 3 (48 hour), n=10,0,0,2 | -0.02 ± 2.170 | — | — | -2 ± 0.990 |
| Hematocrit, Period 2,Day 3 (48 hour), n=0,10,0,2 | — | -0.65 ± 2.991 | — | -3.3 ± 0.424 |
| Hematocrit, Period 3,Day 3 (48 hour), n=0,0,9,2 | — | — | 0.02 ± 2.299 | -2.35 ± 0.495 |
| Hematocrit, Follow-up, n=0,0,9,2 | — | — | -1.67 ± 2.545 | -1.95 ± 2.333 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included SBP, DBP. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| millimeters of mercury | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| SBP, Period 1, Day 1 (2 hours), n=10,0,0,2 | 4.6 ± 10.94 | — | — | 6.0 ± 7.07 |
| SBP, Period 1, Day 2 (24 hours), n=10,0,0,2 | -4.3 ± 11.13 | — | — | 0.5 ± 3.54 |
| SBP, Period 1, Day 3 (48 hours), n=10,0,0,2 | -4.8 ± 8.63 | — | — | -1.5 ± 0.71 |
| SBP, Period 2, Day 1 (2 hours), n=0,10,0,2 | — | 3.5 ± 11.18 | — | 10.5 ± 6.36 |
| SBP, Period 2, Day 2 (24 hours), n=0,10,0,2 | — | -2.0 ± 9.71 | — | 6.0 ± 7.07 |
| SBP, Period 2, Day 3 (48 hours), n=0,10,0,2 | — | 1.2 ± 9.37 | — | -3.5 ± 4.95 |
| SBP, Period 3, Day 1 (2 hours), n=0,0,9,2 | — | — | 7.4 ± 12.89 | -1.0 ± 1.41 |
| SBP, Period 3, Day 2 (24 hours), n=0,0,9,2 | — | — | 4.1 ± 8.19 | -0.5 ± 2.12 |
| SBP, Period 3, Day 3 (48 hours), n=0,0,9,2 | — | — | -0.7 ± 10.65 | 0.0 ± 12.73 |
| SBP, Follow-up, n=0,0,9,2 | — | — | 5.1 ± 7.42 | -4.5 ± 3.54 |
| DBP, Period 1, Day 1 (2 hours), n=10,0,0,2 | 3.4 ± 9.63 | — | — | 5.0 ± 8.49 |
| DBP, Period 1, Day 2 (24 hours), n=10,0,0,2 | -4.4 ± 7.56 | — | — | 0.0 ± 7.07 |
| DBP, Period 1, Day 3 (48 hours), n=10,0,0,2 | -3.7 ± 7.73 | — | — | 2.0 ± 2.83 |
| DBP, Period 2, Day 1 (2 hours), n=0,10,0,2 | — | -3.4 ± 7.73 | — | -4.5 ± 0.71 |
| DBP, Period 2, Day 2 (24 hours), n=0,10,0,2 | — | -2.6 ± 8.97 | — | -4.0 ± 0.00 |
| DBP, Period 2, Day 3 (48 hours), n=0,10,0,2 | — | 0.7 ± 8.81 | — | -4.5 ± 0.71 |
| DBP, Period 3, Day 1 (2 hours), n=0,0,9,2 | — | — | -2.8 ± 13.58 | 4.0 ± 9.90 |
| DBP, Period 3, Day 2 (24 hours), n=0,0,9,2 | — | — | -3.2 ± 3.96 | 4.0 ± 0.00 |
| DBP, Period 3, Day 3 (48 hours), n=0,0,9,2 | — | — | -1.3 ± 9.34 | 3.0 ± 5.66 |
| DBP, Follow-up, n=0,0,9,2 | — | — | 2.2 ± 9.80 | 2.5 ± 3.54 |
Single vital signs were measured in semi-supine position after 5 minutes rest and included heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| beats/minute | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Heart rate, Period 1, Day 1 (2 hours), n=10,0,0,2 | 1.6 ± 8.88 | — | — | 1.0 ± 15.56 |
| Heart rate, Period 2, Day 2 (24 hours), n=10,0,0,2 | 0.1 ± 7.37 | — | — | -4.5 ± 16.26 |
| Heart rate, Period 1, Day 3 (48 hours), n=10,0,0,2 | -3.2 ± 8.27 | — | — | -4.0 ± 15.56 |
| Heart rate, Period 2, Day 1 (2 hours), n=0,10,0,2 | — | 4.9 ± 6.47 | — | 5.0 ± 8.49 |
| Heart rate, Period 2, Day 2 (24 hours), n=0,10,0,2 | — | 0.9 ± 4.89 | — | 2.0 ± 7.07 |
| Heart rate, Period 2, Day 3 (48 hours), n=0,10,0,2 | — | 3.0 ± 4.35 | — | -2.5 ± 0.71 |
| Heart rate, Period 3, Day 1 (2 hours), n=0,0,9,2 | — | — | 4.6 ± 7.65 | 7.0 ± 11.31 |
| Heart rate, Period 3, Day 2 (24 hours), n=0,0,9,2 | — | — | 1.1 ± 6.27 | 0.5 ± 3.54 |
| Heart rate, Period 3, Day 3 (48 hours), n=0,0,9,2 | — | — | 3.2 ± 9.92 | 6.5 ± 12.02 |
| Heart rate, Follow-up, n=0,0,9,2 | — | — | -4.2 ± 8.83 | 0.5 ± 0.71 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that automatically calculated the heart rate. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| beats/minute | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| ECG Heart rate,Period1,Day 1 (2 hours),n=10,0,0,2 | 8.0 ± 7.15 | — | — | 5.0 ± 8.49 |
| ECG Heart rate,Period1,Day 2 (24 hours),n=10,0,0,2 | -0.3 ± 4.11 | — | — | -4.0 ± 4.24 |
| ECG Heart rate,Period1,Day 3 (48 hours),n=10,0,0,2 | 4.8 ± 6.75 | — | — | 0.0 ± 9.90 |
| ECG Heart rate,Period2,Day 1 (2 hours),n=0,10,0,2 | — | 6.4 ± 8.88 | — | 10.0 ± 7.07 |
| ECG Heart rate,Period2,Day 2 (24 hours),n=0,10,0,2 | — | -0.2 ± 8.78 | — | 8.0 ± 8.49 |
| ECG Heart rate,Period2,Day 3 (48 hours),n=0,10,0,2 | — | -0.5 ± 10.32 | — | 3.0 ± 5.66 |
| ECG Heart rate,Period3,Day 1 (2 hours),n=0,0,9,2 | — | — | 8.0 ± 7.04 | 5.5 ± 6.36 |
| ECG Heart rate,Period3,Day 2 (24 hours),n=0,0,9,2 | — | — | 4.6 ± 13.61 | 12.0 ± 15.56 |
| ECG Heart rate,Period3,Day 3 (48 hours),n=0,0,9,2 | — | — | 1.4 ± 5.98 | 5.0 ± 9.90 |
| ECG Heart rate, Follow-up, n=0,0,9,2 | — | — | -3.8 ± 6.72 | -1.0 ± 0.00 |
A 12 lead ECG was measured in semi-supine position after 5 minutes rest using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF for Part 3. Baseline was defined as assessments performed on Day 1 (pre-dose). Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Only those participants with data available at the specified time were analyzed (represented by n=x in the category titles). Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.
| milliseconds | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| PR interval, Period1,Day 1 (2 hours),n=10,0,0,2 | -3.3 ± 12.58 | — | — | -1.0 ± 5.66 |
| PR interval, Period1,Day 2 (24 hours),n=10,0,0,2 | -1.9 ± 7.82 | — | — | -1.0 ± 5.66 |
| PR interval,Period1,Day 3 (48 hours), n=10,0,0,2 | -3.7 ± 9.08 | — | — | 0.0 ± 4.24 |
| PR interval,Period 2,Day 1 (2 hours),n=0,10,0,2 | — | -7.5 ± 12.70 | — | -8.5 ± 0.71 |
| PR interval,Period 2, Day 2 (24 hours),n=0,10,0,2 | — | -2.2 ± 9.02 | — | 1.0 ± 4.24 |
| PR interval, Period2, Day 3 (48 hours),n=0,10,0,2 | — | -3.5 ± 13.92 | — | 3.0 ± 1.41 |
| PR interval,Period 3,Day 1 (2 hours),n=0,0,9,2 | — | — | -0.1 ± 6.77 | -4.0 ± 14.14 |
| PR interval,Period 3,Day 2 (24 hours),n=0,0,9,2 | — | — | 4.8 ± 13.94 | 0.5 ± 7.78 |
| PR interval,Period 3,Day 3 (48 hours), n=0,0,9,2 | — | — | 0.3 ± 16.18 | 4.0 ± 16.97 |
| PR interval, Follow-up, n=0,0,9,2 | — | — | 6.1 ± 11.95 | -6.0 ± 24.04 |
| QRS duration,Period 1,Day 1 (2 hours),n=10,0,0,2 | 2.0 ± 10.73 | — | — | 3.5 ± 9.19 |
| QRS duration,Period 1,Day 2 (24 hours),n=10,0,0,2 | 4.3 ± 8.63 | — | — | -3.0 ± 7.07 |
| QRS duration,Period 1,Day 3 (48 hours),n=10,0,0,2 | 0.5 ± 10.50 | — | — | 2.0 ± 4.24 |
| QRS duration,Period 2,Day 1 (2 hours),n=0,10,0,2 | — | 1.8 ± 4.71 | — | 2.0 ± 7.07 |
| QRS duration,Period 2, Day 2 (24 hours),n=0,10,0,2 | — | 0.4 ± 7.07 | — | -2.5 ± 19.09 |
| QRS duration,Period 2, Day 3 (48 hours),n=0,10,0,2 | — | -1.1 ± 6.40 | — | 1.5 ± 3.54 |
| QRS duration,Period 3,Day 1(2 hours),n=0,0,9,2 | — | — | 2.9 ± 4.65 | 1.5 ± 4.95 |
| QRS duration,Period 3,Day 2(24 hours),n=0,0,9,2 | — | — | -2.6 ± 4.39 | 8.0 ± 8.49 |
| QRS duration,Period3, Day 3(48 hours),n=0,0,9,2 | — | — | -1.1 ± 8.74 | 3.5 ± 14.85 |
| QRS duration, Follow-up, n=0,0,9,2 | — | — | -0.7 ± 6.52 | 4.5 ± 7.78 |
| QT interval,Period 1, Day 1(2 hours),n=10,0,0,2 | -9.2 ± 19.47 | — | — | -15.0 ± 19.80 |
| QT interval,Period 1,Day 2(24 hours),n=10,0,0,2 | 7.9 ± 19.45 | — | — | -6.0 ± 24.04 |
| QT interval,Period 1, Day 3(48 hours),n=10,0,0,2 | 0.4 ± 22.89 | — | — | -0.5 ± 12.02 |
| QT interval,Period 2, Day 1 (2 hours),n=0,10,0,2 | — | -4.0 ± 22.45 | — | -14.5 ± 23.33 |
| QT interval,Period 2, Day 2 (24 hours),n=0,10,0,2 | — | 3.7 ± 15.93 | — | -12.5 ± 31.82 |
| QT interval,Period 2, Day 3 (48 hours),n=0,10,0,2 | — | 0.0 ± 26.86 | — | -3.0 ± 2.83 |
| QT interval,Period 3, Day 1 (2 hours),n=0,0,9,2 | — | — | -7.9 ± 11.61 | -12.5 ± 31.82 |
| QT interval,Period 3, Day 2 (24 hours),n=0,0,9,2 | — | — | -6.2 ± 24.03 | -15.0 ± 28.28 |
| QT interval,Period 3, Day 3 (48 hours),n=0,0,9,2 | — | — | -3.0 ± 15.28 | -15.0 ± 36.77 |
| QT interval, Follow-up, n=0,0,9,2 | — | — | 11.4 ± 17.84 | 8.5 ± 6.36 |
| QTcB ,Period 1, Day 1 (2 hours), n=10,0,0,2 | 16.4 ± 25.48 | — | — | -1.0 ± 2.83 |
| QTcB, Period 1, Day 2 (24 hours), n=10,0,0,2 | 8.6 ± 16.10 | — | — | -19.5 ± 9.19 |
| QTcB, Period 1, Day 3 (48 hours), n=10,0,0,2 | 15.7 ± 14.70 | — | — | -1.0 ± 19.80 |
| QTcB, Period 2, Day 1 (2 hours), n=0,10,0,2 | — | 15.1 ± 20.18 | — | 15.0 ± 8.49 |
| QTcB, Period 2, Day 2 (24 hours), n=0,10,0,2 | — | 5.1 ± 13.98 | — | 9.5 ± 12.02 |
| QTcB, Period 2, Day 3 (48 hours), n=0,10,0,2 | — | 1.8 ± 12.99 | — | 5.5 ± 13.44 |
| QTcB, Period 3, Day 1 (2 hours), n=0,0,9,2 | — | — | 14.9 ± 21.83 | 4.0 ± 14.14 |
| QTcB, Period 3, Day 2 (24 hours), n=0,0,9,2 | — | — | 5.8 ± 11.14 | 18.5 ± 12.02 |
| QTcB, Period 3, Day 3 (48 hours), n=0,0,9,2 | — | — | 2.1 ± 10.02 | -3.0 ± 8.49 |
| QTcB, Follow-up, n=0,0,9,2 | — | — | 1.9 ± 14.88 | 6.5 ± 6.36 |
| QTcF, Period 1, Day 1 (2 hours), n=10,0,0,2 | 7.7 ± 20.94 | — | — | -6.0 ± 5.66 |
| QTcF, Period 1, Day 2 (24 hours), n=10,0,0,2 | 8.3 ± 16.09 | — | — | -15.0 ± 14.14 |
| QTcF, Period 1, Day 3 (48 hours), n=10,0,0,2 | 10.5 ± 14.75 | — | — | -1.0 ± 8.49 |
| QTcF, Period 2, Day 1 (2 hours), n=0,10,0,2 | — | 8.4 ± 17.65 | — | 5.0 ± 14.14 |
| QTcF, Period 2, Day 2 (24 hours), n=0,10,0,2 | — | 4.5 ± 7.09 | — | 2.5 ± 19.09 |
| QTcF, Period 2, Day 3 (48 hours), n=0,10,0,2 | — | 1.2 ± 10.25 | — | 2.5 ± 7.78 |
| QTcF, Period 3, Day 1 (2 hours), n=0,0,9,2 | — | — | 6.8 ± 16.15 | -1.5 ± 20.51 |
| QTcF, Period 3, Day 2 (24 hours), n=0,0,9,2 | — | — | 1.2 ± 4.99 | 7.0 ± 2.83 |
| QTcF, Period 3, Day 3 (48 hours), n=0,0,9,2 | — | — | 0.2 ± 9.18 | -7.0 ± 18.38 |
| QTcF, Follow-up, n=0,0,9,2 | — | — | 5.2 ± 13.55 | 7.0 ± 7.07 |
Urinalysis parameters assessed were urine ketones, urine glucose, urine occult blood, urine pH, urine specific gravity and urine protein. In this dipstick test, the level of ketones, glucose, occult blood, pH, specific gravity and protein in urine samples was recorded as negative trace, 1+, 3+, 5+, 6+, 7+ and 8+ (the plus sign increases with a higher level of ketones, occult blood, pH or specific gravity in the urine: 1+=slightly positive, 3+ to 5+=positive, 6+ and above=high positive). Urine samples were collected for the measurement of urinalysis parameters by dipstick method up-to follow-up (5 to 7 days post last dose) in Part 3. Only categories with significant values have been presented.
| Participants | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|
| Urine Ketones, Follow-up, 1+ | 0 | 0 | 1 | 0 |
| Urine Occult blood,Trace,Period 1, Day 3 (48hours) | 2 | 0 | 0 | 0 |
| Urine Occult blood,Period 1,Day 3 (48hours), 1+ | 0 | 0 | 0 | 1 |
| Urine Occult blood,Period 1,Day 3 (48hours), 3+ | 1 | 0 | 0 | 0 |
| Urine Occult blood,Trace,Period 2,Day 3 (48hours) | 0 | 1 | 0 | 0 |
| Urine Occult blood,Period 2,Day 3 (48hours), 1+ | 0 | 1 | 0 | 0 |
| Urine Occult blood,Trace,Period 3,Day 3 (48hours) | 0 | 0 | 2 | 0 |
| Urine Occult blood,Period 3,Day 3 (48hours), 1+ | 0 | 0 | 1 | 0 |
| Urine Occult blood, Follow-up, 4+ | 0 | 0 | 1 | 0 |
| Urine pH, Period 1 Day 3 (48 hours), 5+ | 0 | 0 | 0 | 1 |
| Urine pH, Period 1, Day 3 (48 hours), 6+ | 4 | 0 | 0 | 1 |
| Urine pH, Period 1, Day 3 (48 hours), 7+ | 5 | 0 | 0 | 1 |
| Urine pH, Period 1, Day 3 (48 hours), 8+ | 1 | 0 | 0 | 0 |
| Urine pH, Period 2, Day 3 (48 hours), 5+ | 0 | 6 | 0 | 2 |
| Urine pH, Period 2, Day 3 (48 hours), 6+ | 0 | 2 | 0 | 0 |
| Urine pH, Period 2, Day 3 (48 hours), 7+ | 0 | 2 | 0 | 0 |
| Urine pH, Period 3, Day 3 (48 hours), 5+ | 0 | 0 | 3 | 0 |
| Urine pH, Period 3, Day 3 (48 hours), 6+ | 0 | 0 | 5 | 2 |
| Urine pH, Period 3, Day 3 (48 hours), 7+ | 0 | 0 | 1 | 0 |
| Urine pH, Follow-up, 5+ | 0 | 0 | 3 | 1 |
| Urine pH, Follow-up, 6+ | 0 | 0 | 2 | 1 |
| Urine pH, Follow-up, 7+ | 0 | 0 | 4 | 0 |
| Urine Specific gravity, Period1,Day 3(48 hours),1+ | 10 | 0 | 0 | 2 |
| Urine Specific gravity, Period2,Day 3(48 hours),1+ | 0 | 10 | 0 | 2 |
| Urine Specific gravity,Period 3,Day 3(48 hours),1+ | 0 | 0 | 9 | 2 |
| Urine Specific gravity, Follow-up, 1+ | 0 | 0 | 9 | 2 |
Collected over Non-serious AEs and SAEs were collected from Day 1 until follow-up (Up to 14 days in Part 1a, 11 days in Part 1b and 2 and 14 days in Part 3).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gepotidacin 1500 mg - R Capsules | 0/26 (0%) | 0/26 (0%) | 8/26 (30.8%) |
| Gepotidacin 1500 mg RC Tablets | 0/26 (0%) | 0/26 (0%) | 5/26 (19.2%) |
| Gepotidacin 1500 mg HSWG Tablets | 0/26 (0%) | 0/26 (0%) | 9/26 (34.6%) |
| Gepotidacin RC 1500 mg Tablets | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Gepotidacin RC 3000 mg Tablets | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Gepotidacin RC 1500 mg Fed | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Gepotidacin RC 2250 mg Fed | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Gepotidacin RC 3000 mg Fed | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Gepotidacin 1500 mg - R Capsules | Gepotidacin 1500 mg RC Tablets | Gepotidacin 1500 mg HSWG Tablets | Gepotidacin RC 1500 mg Tablets | Gepotidacin RC 3000 mg Tablets | Gepotidacin RC 1500 mg Fed | Gepotidacin RC 2250 mg Fed | Gepotidacin RC 3000 mg Fed | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/26 | 5/26 | 6/26 | 5/10 | 9/10 | 0/10 | 0/10 | 1/9 | 0/2 |
| NauseaGastrointestinal disorders | 1/26 | 1/26 | 2/26 | 0/10 | 6/10 | 0/10 | 0/10 | 4/9 | 0/2 |
| VomitingGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/10 | 5/10 | 0/10 | 0/10 | 1/9 | 0/2 |
| DizzinessNervous system disorders | 1/26 | 0/26 | 0/26 | 1/10 | 4/10 | 0/10 | 0/10 | 1/9 | 0/2 |
| HeadacheNervous system disorders | 0/26 | 0/26 | 1/26 | 2/10 | 3/10 | 0/10 | 0/10 | 2/9 | 0/2 |
| Abdominal discomfortGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/10 | 0/10 | 0/10 | 0/10 | 2/9 | 0/2 |
| Faeces softGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/10 | 0/10 | 0/10 | 1/10 | 2/9 | 0/2 |
| Abdominal painGastrointestinal disorders | 2/26 | 2/26 | 5/26 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 | 0/2 |
| Abdominal pain upperGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 | 0/2 |
| Paraesthesia oralGastrointestinal disorders | 0/26 | 0/26 | 0/26 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 | 0/2 |
| Age, Continuous(Years) | Total Participants-Part 1a | Total Participants-Part 2 | Total Participants- Part 3 | Total |
|---|---|---|---|---|
| Mean | 39.5 ± 10.64 | 55.6 ± 6.43 | 37.8 ± 7.93 | 42.5 ± 11.39 |
| Sex: Female, Male(Participants) | Total Participants-Part 1a | Total Participants-Part 2 | Total Participants- Part 3 | Total |
|---|---|---|---|---|
| Female | 5 | 8 | 6 | 19 |
| Male | 21 | 2 | 6 | 29 |
| Race/Ethnicity, Customized(Participants) | Total Participants-Part 1a | Total Participants-Part 2 | Total Participants- Part 3 | Total |
|---|---|---|---|---|
| Black or African American | 10 | 0 | 0 | 10 |
| White - White/Caucasian/European Heritage | 16 | 0 | 0 | 16 |
| Asian - Japanese Heritage | 0 | 10 | 12 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Oct 2017, 14 months.
Results were first posted in Nov 2018, 1 year after primary completion.
Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 14 months is above that.
Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin